0001404644-26-000037
SEC filingDeepening operating losses reflect increased R&D headcount and clinical trial costs for NGN-401, partially offset by program prioritization savings.
Operating loss for the first quarter of 2026 was $33.3 million, compared to $25.9 million in the same period last year, a 28.7% increase. This expansion was primarily driven by higher research and development expenses, including increased headcount and laboratory consumables related to chemistry, manufacturing, and controls (CMC) for the lead program NGN-401. The company completed enrollment in the Phase 1/2 trial and initiated dosing in the Embolden registrational trial in Q4 2025, reflecting continued investment in its Rett syndrome program.
Net loss increased 36.6% to $30.9 million from $22.6 million in the prior year quarter. The net loss growth outpaced the operating loss increase due to lower interest income, resulting from a decrease in short-term investments and lower yields on cash, cash equivalents, and short-term investment balances. Diluted EPS was -$1.39, compared to -$1.08 in the prior year quarter.
The decrease in Batten disease program expenses reflects the company's decision to de-prioritize NGN-101 following the FDA's denial of a Regenerative Medicine Advanced Therapy (RMAT) designation, which precluded a streamlined registrational pathway. This strategic shift allows Neurogene to concentrate resources on its lead program, NGN-401 for Rett syndrome, which has received Breakthrough Therapy and RMAT designations and is enrolled in the FDA's START pilot program. The company completed enrollment in the Phase 1/2 trial and initiated dosing in the Embolden registrational trial in Q4 2025. Management expects general and administrative expenses to increase as the company scales operations to support potential commercialization.
Management bases its projections of operating capital requirements on its current operating plan, which includes several assumptions that may prove incorrect. The company may use all available capital resources sooner than expected. Operating plans may change, and additional capital may be needed to meet capital requirements. Management will continue to evaluate the nature and extent of potential impacts to the business, results of operations, liquidity, and capital resources.